Front. Oncol. Frontiers in Oncology Front. Oncol. 2234-943X Frontiers Media S.A. 10.3389/fonc.2023.1233247 Oncology Correction Corrigendum: Transarterial chemoembolization combined with lenvatinib versus transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: a systematic review and meta-analysis Liu Jun-Ning Li Ji-Jiang Yan Shu Zhang Guang-Nian Yi Peng-Sheng * Department of Hepato-Biliary-Pancreas II, Affiliated Hospital of North Sichuan Medical College, Nanchong, China

Approved by: Frontiers Editorial Office, Frontiers Media SA, Switzerland

*Correspondence: Peng-Sheng Yi, liujunning98@163.com

22 06 2023 2023 13 1233247 01 06 2023 14 06 2023 Copyright © 2023 Liu, Li, Yan, Zhang and Yi 2023 Liu, Li, Yan, Zhang and Yi

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

 A Corrigendum on Transarterial chemoembolization combined with lenvatinib versus transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: A systematic review and meta-analysis by Liu J-N, Li J-J, Yan S, Zhang G-N and Yi P-S (2023) Front. Oncol. 13:1074793. doi: 10.3389/fonc.2023.1074793 hepatocellular carcinoma (HCC) lenvatinib sorafenib (nexavar) transarterial chemoembolization (TACE) combination therapy section-in-acceptance Gastrointestinal Cancers: Hepato Pancreatic Biliary Cancers

Error in Figure

In the published article, there was an error in Figure 2 as published. The two labels “Favours [LEN+TACE]” and “Favours [SOR+TACE]” located on the left and right below the X-axis, should read “Favours [SOR+TACE]” and “Favours [LEN+TACE]” respectively. The corrected Figure 2 and its caption “Forest plots for the comparison of (A) objective response rate (ORR) and disease control rate (DCR), and (B) complete response (CR), partial response (PR), stable disease (SD) and progressive disease (PD)” appear below.

Forest plots for the comparison of (A) objective response rate (ORR) and disease control rate (DCR), and (B) complete response (CR), partial response (PR), stable disease (SD) and progressive disease (PD).

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.